DR negativity is a distinctive feature of M1/M2 AML cases with NPM1 mutation

Leuk Res. 2008 Jul;32(7):1141-3. doi: 10.1016/j.leukres.2007.11.017. Epub 2008 Jan 3.

Abstract

Our previous observation of a higher incidence of FLT3-ITD in DR(-) M1/M2 AML than in DR(+) M1/M2 led to an investigation of NPM1 mutation in the same samples, since DR(-) AML and AML with NPM1 mutation share such characteristics as normal karyotype, the absence of CD34, and FLT3-ITD. NPM1 mutation was found in 18 of 26 (69.2%) of DR(-) cases, but not in any of 28 DR(+) cases. FLT3-ITD was noted in 66.7% of the cases with NPM1 mutation. These findings point to DR negativity as another phenotypic feature of AML with NPM1 mutation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Base Sequence
  • DNA, Complementary
  • HLA-DR Antigens / analysis*
  • Humans
  • Leukemia, Myeloid, Acute / genetics*
  • Leukemia, Myeloid, Acute / immunology
  • Nucleophosmin
  • Reverse Transcriptase Polymerase Chain Reaction

Substances

  • DNA, Complementary
  • HLA-DR Antigens
  • NPM1 protein, human
  • Nucleophosmin